Page 125 - 《中国药房》2025年2期

参考文献 vironment in EGFR mutation-positive non-small cell lung
[ 1 ] SU C X. Emerging insights to lung cancer drug resistance cancer[J]. Clin Cancer Res，2020，26（8）：2037-2046.
[J]. Cancer Drug Resist，2022，5（3）：534-540. [13] FANG Y S，WANG Y Y，ZENG D Q，et al. Comprehen‐
[ 2 ] JIA Y J，LI X F，JIANG T，et al. EGFR-targeted therapy sive analyses reveal TKI-induced remodeling of the tumor
alters the tumor microenvironment in EGFR-driven lung immune microenvironment in EGFR/ALK-positive non-
tumors：implications for combination therapies[J]. Int J small-cell lung cancer[J]. Oncoimmunology，2021，10（1）：
Cancer，2019，145（5）：1432-1444. 1951019.
[ 3 ] PENG S L，WANG R，ZHANG X J，et al. EGFR-TKI [14] WATERHOUSE D M，GARON E B，CHANDLER J，et
resistance promotes immune escape in lung cancer via al. Continuous versus 1-year fixed-duration nivolumab in
increased PD-L1 expression[J]. Mol Cancer，2019，18 previously treated advanced non-small-cell lung cancer：
（1）：165. CHECKMATE 153[J]. J Clin Oncol，2020，38（33）：3863-
[ 4 ] ZHOU J，YU X，HOU L K，et al. Epidermal growth factor 3873.
receptor tyrosine kinase inhibitor remodels tumor microen‐ [15] BORGHAEI H，PAZ-ARES L，HORN L，et al. Ni-
vironment by upregulating LAG-3 in advanced non-small- volumab versus docetaxel in advanced nonsquamous non-
cell lung cancer[J]. Lung Cancer，2021，153：143-149. small-cell lung cancer[J]. N Engl J Med，2015，373（17）：
[ 5 ] 刘尧尧，苗健龙 . 免疫治疗在 EGFR 突变晚期非小细胞 1627-1639.
肺癌中的研究进展[J]. 中国肺癌杂志，2023，26（12）： [16] HAYASHI H，SUGAWARA S，FUKUDA Y，et al. A ran‐
934-942. domized phase Ⅱ study comparing nivolumab（NIVO）
LIU Y Y，MIAO J L. Progress of immunotherapy in with carboplatin-pemetrexed（CbPEM） for patients with
EGFR-mutated advanced non-small cell lung cancer[J]. EGFR mutation-positive non-small cell lung cancer
Zhongguo Fei Ai Za Zhi，2023，26（12）：934-942. （NSCLC） who acquire resistance to tyrosine kinase in‐
[ 6 ] TAO L L，HUANG G C，SONG H Z，et al. Cancer asso- hibitors（TKIs） not due to a secondary T790M mutation
ciated fibroblasts：an essential role in the tumor microen- （WJOG8515L）[J]. J Clin Oncol，2021，39（15 Suppl.）：
vironment[J]. Oncol Lett，2017，14（3）：2611-2620. 9037.
[ 7 ] LU C H，GAO Z Y，WU D，et al. Understanding the dy‐ [17] HAYASHI H，SUGAWARA S，FUKUDA Y，et al. A ran‐
namics of TKI-induced changes in the tumor immune mi‐ domized phase Ⅱ study comparing nivolumab with
croenvironment for improved therapeutic effect[J]. J Im‐ carboplatin-pemetrexed for EGFR-mutated NSCLC with
munother Cancer，2024，12（6）：e009165. resistance to EGFR tyrosine kinase inhibitors（WJOG8515L）
[ 8 ] KAWANA S，SAITO R，MIKI Y，et al. Suppression of tu‐ [J]. Clin Cancer Res，2022，28（5）：893-902.
mor immune microenvironment via microRNA-1 after epi‐ [18] LEE C K，MAN J，LORD S，et al. Checkpoint inhibitors
dermal growth factor receptor-tyrosine kinase inhibitor in metastatic EGFR-mutated non-small cell lung cancer：a
resistance acquirement in lung adenocarcinoma[J]. Cancer meta-analysis[J]. J Thorac Oncol，2017，12（2）：403-407.
Med，2021，10（2）：718-727. [19] GARASSINO M C，CHO B C，KIM J H，et al. Dur‐
[ 9 ] LU J Y，LI J W，LIN Z Y，et al. Reprogramming of TAMs valumab as third-line or later treatment for advanced non-
via the STAT3/CD47-SIRPα axis promotes acquired resis‐ small-cell lung cancer（ATLANTIC）：an open-label，
tance to EGFR-TKIs in lung cancer[J]. Cancer Lett，2023， single-arm，phase 2 study[J]. Lancet Oncol，2018，19（4）：
564：216205. 521-536.
[10] TANG J，LIU X L，GONG Y L，et al. Epidermal growth [20] PETERS S，GETTINGER S，JOHNSON M L，et al. Phase
factor receptor tyrosine kinase inhibitors（EGFR-TKIs） Ⅱ trial of atezolizumab as first-line or subsequent therapy
impact on immune microenvironment in non-small cell for patients with programmed death-ligand 1-selected
lung cancer（NSCLC）[J]. J Clin Oncol，2018，36（Suppl. advanced non-small-cell lung cancer（BIRCH）[J]. J Clin
15）：e21154. Oncol，2017，35（24）：2781-2789.
[11] GAO X D，SUI H S，ZHAO S，et al. Immunotherapy tar‐ [21] NOSAKI K，SAKA H，HOSOMI Y，et al. Safety and effi‐
geting myeloid-derived suppressor cells（MDSCs）in tu‐ cacy of pembrolizumab monotherapy in elderly patients
mor microenvironment[J]. Front Immunol，2021，11： with PD-L1-positive advanced non-small-cell lung cancer：
585214. pooled analysis from the KEYNOTE-010，KEYNOTE-
[12] ISOMOTO K，HARATANI K，HAYASHI H，et al. Impact 024，and KEYNOTE-042 studies[J]. Lung Cancer，2019，
of EGFR-TKI treatment on the tumor immune microen- 135：188-195.

中国药房 2025年第36卷第2期 China Pharmacy 2025 Vol. 36 No. 2 · 243 ·